Digital therapeutics (DTx) are applied healthcare technologies designed to prevent, manage, or treat health conditions. In pediatric pain, DTx can enhance access to evidence-based, effective pain assessment and management. This article explores technologies such as artificial intelligence (AI), extended reality (XR), mobile health (mHealth), and sensors (eg, smartwatches). Equitable DTx deployment can address geographic disparities by enabling on-demand pain care, necessitating an intelligent learning DTx-enabled health system. Ensuring safety will require comprehensive regulatory frameworks at national and international levels. Achieving this transformation requires robust regulatory frameworks, workforce training, and equitable codesign to ensure accessible, evidence-based care for all pediatric populations.

Background: Tobacco and cannabis are among the most widely used substances globally, and rates of co-use are on the rise. Understanding the impact of inhaled tobacco-cannabis co-use on health outcomes and tobacco cessation is critical for guiding patients and clinicians. Objectives: To summarize the existing evidence, identify knowledge gaps, and prioritize research questions related to effects of inhaled tobacco-cannabis co-use on tobacco cessation and lung health. Methods: A multidisciplinary committee was convened to review the evidence, identify knowledge gaps, and develop research questions in four priority research areas: 1) common data elements and terminology, 2) patterns and prevalence of co-use, 3) impact of co-use on tobacco cessation, and 4) effects of co-use on lung health. A modified Delphi process was conducted in three rounds to reach consensus on prioritizing research questions. Results: The evidence reviewed by the expert panel in four priority research areas yielded the following gaps in the literature with high priority to address with future research: 1) lack of consensus on terminology and recommended co-use data elements, 2) limited research on co-use and tobacco-related disparities, 3) insufficient evidence on how cannabis use affects tobacco cessation, and 4) alarming yet inconsistent findings on the effects of co-use on lung health. Conclusions: This statement outlines and guides a research agenda on the effects of inhaled tobacco-cannabis co-use on tobacco cessation and lung health. Consensus-driven recommendations include adopting harmonized terms and minimum data elements, studying the prevalence of co-use among populations experiencing tobacco-related disparities, evaluating the impact of co-use on tobacco cessation pharmacotherapies, and assessing the effects of co-use on the development and progression of lung diseases.

J Rheumatol 2025; doi: 10.3899/jrheum.2025-0268 The affiliation for Tommy Kok Annfeldt should be Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. This correction applies only to the August 5 First Release. The correct affiliation appears in the print and online issues. doi: 10.3899/jrheum.2025-0268.C1.